1. Clinical & Scientific Overview
Gabapentin (TIP-MED-000111, Reference Code [7.9]) is classified under
Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07) as a Gabapentinoid; Voltage-Gated Calcium Channel Alpha-2-Delta (α2δ) Subunit Ligand.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 07 [7.9], p. 83): Neurontin (Pfizer), Gabapin / Gabapin-NT (Intas), Gabantin (Sun Pharma), Pentanerv (Alkem) — Strengths & Dosage Forms: Oral Capsules / Tablets: 100 mg, 300 mg, 400 mg, 600 mg; Sustained-Release: 450 mg SR, 600 mg SR
Oral Capsules / Tablets: 100 mg, 300 mg, 400 mg, 600 mg; Sustained-Release: 450 mg SR, 600 mg SR
3. Mechanism of Action & Pharmacodynamics
Gabapentinoid; Voltage-Gated Calcium Channel Alpha-2-Delta (α2δ) Subunit Ligand acting on target receptor/enzyme pathways in Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07): clinical efficacy is mediated via Gabapentinoid; Voltage-Gated Calcium Channel Alpha-2-Delta (α2δ) Subunit Ligand for Post-herpetic neuralgia; diabetic peripheral neuropathy and radicular neuropathic pain; adjunctive therapy in focal seizures; restless legs syndrome; uremic pruritus in haemodialysis patients (very low post-dialysis dose: 100 mg)..
4. Therapeutic Indications & Evidence-Supported Uses
- Post-herpetic neuralgia
- diabetic peripheral neuropathy and radicular neuropathic pain
- adjunctive therapy in focal seizures
- restless legs syndrome
- uremic pruritus in haemodialysis patients (very low post-dialysis dose: 100 mg)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Neuropathic Pain: Initiate at 100 mg to 300 mg once daily at bedtime on Day 1, 100–300 mg twice daily on Day 2, and 100–300 mg three times daily on Day 3; titrate gradually to 900–1800 mg/day in 3 divided doses. Dosing strictly depends on renal CrCl! Follow physician prescription.
Administration & Meal Timing: With or without food (unlike pregabalin, gabapentin relies on a saturable L-amino acid transporter [LAT1] in the proximal small intestine—absorption drops from 60% at 300 mg to 33% at 1200 mg, so dividing doses TDS improves bioavailability). | At bedtime initially; three times daily (every 8 hours, with max 12 hours between evening and morning dose) for maintenance.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted 100% unchanged in urine)! • CrCl ≥60 mL/min: 300–600 mg TDS. • CrCl 30–59 mL/min: 200–300 mg twice daily (400–700 mg/day). • CrCl 15–29 mL/min: 100–300 mg once daily (200–300 mg/day). • CrCl <15 mL/min: 100 mg once daily or alternate days (Dialysis: 100–300 mg after each haemodialysis session only!). Hepatic: Safe in liver disease.
Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted 100% unchanged in urine)! • CrCl ≥60 mL/min: 300–600 mg TDS. • CrCl 30–59 mL/min: 200–300 mg twice daily (400–700 mg/day). • CrCl 15–29 mL/min: 100–300 mg once daily (200–300 mg/day). • CrCl <15 mL/min: 100 mg once daily or alternate days (Dialysis: 100–300 mg after each haemodialysis session only!). Hepatic: Safe in liver disease.
Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted 100% unchanged in urine)! • CrCl ≥60 mL/min: 300–600 mg TDS. • CrCl 30–59 mL/min: 200–300 mg twice daily (400–700 mg/day). • CrCl 15–29 mL/min: 100–300 mg once daily (200–300 mg/day). • CrCl <15 mL/min: 100 mg once daily or alternate days (Dialysis: 100–300 mg after each haemodialysis session only!). Hepatic: Safe in liver disease.
7. Contraindications, Precautions & High-Risk Warnings
- Same class warnings as pregabalin: respiratory depression when combined with opioids/CNS depressants or in COPD/elderly; avoid abrupt withdrawal.
Key Clinical Precautions: Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted 100% unchanged in urine)! • CrCl ≥60 mL/min: 300–600 mg TDS. • CrCl 30–59 mL/min: 200–300 mg twice daily (400–700 mg/day). • CrCl 15–29 mL/min: 100–300 mg once daily (200–300 mg/day). • CrCl <15 mL/min: 100 mg once daily or alternate days (Dialysis: 100–300 mg after each haemodialysis session only!). Hepatic: Safe in liver disease.
8. Adverse Effects Profile
- Somnolence, dizziness, ataxia/gait unsteadiness, fatigue, peripheral pedal oedema, weight gain, nystagmus.
- Severe neurotoxicity (myoclonus, asterixis, encephalopathy, coma) if unadjusted doses are given in renal failure; respiratory depression with opioids; falls; angioedema.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Magnesium/Aluminium Antacids (Digene/Gelusil): Reduce oral bioavailability of gabapentin by ~20%—take gabapentin at least 2 hours AFTER an antacid! Additive CNS/respiratory depression with opioids (tramadol), benzodiazepines, zolpidem, antidepressants, and alcohol
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Take the first few doses at bedtime until you know how drowsy it makes you feel. Keep a 2-hour gap from antacid gels. Do not stop taking gabapentin suddenly.
- Meal & Clock Timing Instruction: With or without food (unlike pregabalin, gabapentin relies on a saturable L-amino acid transporter [LAT1] in the proximal small intestine—absorption drops from 60% at 300 mg to 33% at 1200 mg, so dividing doses TDS improves bioavailability). (At bedtime initially; three times daily (every 8 hours, with max 12 hours between evening and morning dose) for maintenance.)
- Missed Dose Protocol: Take as soon as remembered unless within 4 hours of the next scheduled dose; never double.
- Geriatric Dispensing Pearl: Start at 100 mg at bedtime in elderly patients (rather than 300 mg), check renal clearance before up-titrating, and avoid FDCs containing nortriptyline or amitriptyline (Gabapin-NT / Gabapin-AT) in patients >65 years.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Capsules / Tablets: 100 mg, 300 mg, 400 mg, 600 mg; Sustained-Release: 450 mg SR, 600 mg SR
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 07 [7.9] (p. 83)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [7.11] Febuxostat — Non-Purine Selective Xanthine Oxidase Inhibitor; Urate-Lowering A
- [7.12] Methotrexate (Low-Dose Weekly Immunomodulator / DMARD Regimen) — Folate Antimetabolite (Dihydrofolate Reductase & AICAR Transformy
- [7.13] Thiocolchicoside, Tolperisone Hydrochloride & Chlorzoxazone (Spinal & Central Muscle Relaxants) — Centrally Acting Skeletal Muscle Relaxants & Antispasticity Agent
- [7.14] Piroxicam & Meloxicam — Long-Half-Life Oxicam NSAIDs — Non-Selective & Preferential COX-2
